- c-Met: c-Met is a receptor tyrosine kinase that is highly expressed in IDH-wildtype glioblastoma cancer cells. It is involved in various tumorigenic and stem cell-enriching pathways, including epithelial-to-mesenchymal transition, angiogenesis, proliferation, and invasion/metastasis. c-Met has been implicated in therapeutic resistance and recurrence, and its expression is associated with poor survival in patients with IDH-wildtype glioblastoma.
- EGFR: EGFR is a receptor tyrosine kinase that is co-expressed with c-Met in IDH-wildtype glioblastoma cancer cells. EGFR and c-Met have been shown to interact and promote cancer progression and malignancy. Inhibition of both EGFR and c-Met has been proposed as a promising therapeutic approach for IDH-wildtype glioblastoma.
- MET: MET is a receptor tyrosine kinase that is highly expressed in IDH-wildtype glioblastoma cancer cells. It is involved in various tumorigenic and stem cell-enriching pathways, including epithelial-to-mesenchymal transition, angiogenesis, proliferation, and invasion/metastasis. MET has been implicated in therapeutic resistance and recurrence, and its expression is associated with poor survival in patients with IDH-wildtype glioblastoma.
- VEGFR: VEGFR is a receptor tyrosine kinase that is involved in angiogenesis and is expressed in IDH-wildtype glioblastoma cancer cells. VEGFR has been shown to interact with c-Met and promote cancer progression and malignancy. Inhibition of both VEGFR and c-Met has been proposed as a promising therapeutic approach for IDH-wildtype glioblastoma.
- PDGFR: PDGFR is a receptor tyrosine kinase that is involved in angiogenesis and is expressed in IDH-wildtype glioblastoma cancer cells. PDGFR has been shown to interact with c-Met and promote cancer progression and malignancy. Inhibition of both PDGFR and c-Met has been proposed as a promising therapeutic approach for IDH-wildtype glioblastoma.
- KIT: KIT is a receptor tyrosine kinase that is involved in angiogenesis and is expressed in IDH-wildtype glioblastoma cancer cells. KIT has been shown to interact with c-Met and promote cancer progression and malignancy. Inhibition of both KIT and c-Met has been proposed as a promising therapeutic approach for IDH-wildtype glioblastoma.
- TIE2: TIE2 is a receptor tyrosine kinase that is involved in angiogenesis and is expressed in IDH-wildtype glioblastoma cancer cells. TIE2 has been shown to interact with c-Met and promote cancer progression and malignancy. Inhibition of both TIE2 and c-Met has been proposed as a promising therapeutic approach for IDH-wildtype glioblastoma.
- TrkA-B: TrkA-B is a receptor tyrosine kinase that is involved in angiogenesis and is expressed in IDH-wildtype glioblastoma cancer cells. TrkA-B has been shown to interact with c-Met and promote cancer progression and malignancy. Inhibition of both TrkA-B and c-Met has been proposed as a promising therapeutic approach for IDH-wildtype glioblastoma.
- CD133: CD133 is a transmembrane phosphoglycoprotein that is highly expressed in IDH-wildtype glioblastoma cancer cells. It is a marker of cancer stem cells and is associated with higher clonogenic survival. Inhibition of CD133 has been proposed as a potential therapeutic approach for IDH-wildtype glioblastoma.
- CD15: CD15 is a transmembrane phosphoglycoprotein that is highly expressed in IDH-wildtype glioblastoma cancer cells. It is a marker of cancer stem cells and is associated with higher clonogenic survival. Inhibition of CD15 has been proposed as a potential therapeutic approach for IDH-wildtype glioblastoma.
- Oct4: Oct4 is a transcription factor that is involved in the self-renewal of embryonic stem cells and is expressed in IDH-wildtype glioblastoma cancer cells. It is a marker of cancer stem cells and is associated with higher clonogenic survival. Inhibition of Oct4 has been proposed as a potential therapeutic approach for IDH-wildtype glioblastoma.
- Nanog: Nanog is a transcription factor that is involved in the self-renewal of embryonic stem cells and is expressed in IDH-wildtype glioblastoma cancer cells. It is a marker of cancer stem cells and is associated with higher clonogenic survival. Inhibition of Nanog has been proposed as a potential therapeutic approach for IDH-wildtype glioblastoma.
- Klf4: Klf4 is a transcription factor that is involved in the self-renewal of embryonic stem cells and is expressed in IDH-wildtype glioblastoma cancer cells. It is a marker of cancer stem cells and is associated with higher clonogenic survival. Inhibition of Klf4 has been proposed as a potential therapeutic approach for IDH-wildtype glioblastoma.
- JARID 1B: JARID 1B is a histone demethylase protein that is highly expressed in IDH-wildtype glioblastoma cancer cells. It is involved in the activation of c-Met and the expression of stem cell markers. Inhibition of JARID 1B has been proposed as a potential therapeutic approach for IDH-wildtype glioblastoma.
- HGF/SF: HGF/SF is a ligand for c-Met that is highly expressed in IDH-wildtype glioblastoma cancer cells. It is involved in various tumorigenic and stem cell-enriching pathways, including epithelial-to-mesenchymal transition, angiogenesis, proliferation, and invasion/metastasis. HGF/SF has been implicated in therapeutic resistance and recurrence, and its expression is associated with poor survival in patients with IDH-wildtype glioblastoma.
- WNT/β-catenin: WNT/β-catenin is a signaling pathway that is highly expressed in IDH-wildtype glioblastoma cancer cells. It is involved in various tumorigenic and stem cell-enriching pathways, including epithelial-to-mesenchymal transition, angiogenesis, proliferation, and invasion/metastasis. WNT/β-catenin has been implicated in therapeutic resistance and recurrence, and its expression is associated with poor survival in patients with IDH-wildtype glioblastoma.
- SPINT2/HAI-2: SPINT2/HAI-2 is a serine peptidase inhibitor that is highly expressed in IDH-wildtype glioblastoma cancer cells. It is an inhibitor of HGF/c-Met signaling and is involved in the regulation of cell proliferation and migration. Inhibition of SPINT2/HAI-2 has been proposed as a potential therapeutic approach for IDH-wildtype glioblastoma.
- EZH2: EZH2 is a histone methyltransferase that is highly expressed in IDH-wildtype glioblastoma cancer cells. It is involved in the regulation of gene expression and is associated with poor survival in patients with IDH-wildtype glioblastoma. Inhibition of EZH2 has been proposed as a potential therapeutic approach for IDH-wildtype glioblastoma.
- BMI1: BMI1 is a transcription factor that is highly expressed in IDH-wildtype glioblastoma cancer cells. It is involved in the regulation of gene expression and is associated with poor survival in patients with IDH-wildtype glioblastoma. Inhibition of BMI1 has been proposed as a potential therapeutic approach for IDH-wildtype glioblastoma.
- CHD5: CHD5 is a chromatin remodeling protein that is highly expressed in IDH-wildtype glioblastoma cancer cells. It is involved in the regulation of gene expression and is associated with poor survival in patients with IDH-wildtype glioblastoma. Inhibition of CHD5 has been proposed as a potential therapeutic approach for IDH-wildtype glioblastoma.
- SOX2: SOX2 is a transcription factor that is highly expressed in IDH-wildtype glioblastoma cancer cells. It is involved in the regulation of gene expression and is associated with poor survival in patients with IDH-wildtype glioblastoma. Inhibition of SOX2 has been proposed as a potential therapeutic approach for IDH-wildtype glioblastoma.
- STAT3: STAT3 is a transcription factor that is highly expressed in IDH-wildtype glioblastoma cancer cells. It is involved in the regulation of gene expression and is associated with poor survival in patients with IDH-wildtype glioblastoma. Inhibition of STAT3 has been proposed as a potential therapeutic approach for IDH-wildtype glioblastoma.
- PIK3CA: PIK3CA is a kinase that is highly expressed in IDH-wildtype glioblastoma cancer cells. It is involved in the regulation of cell survival and proliferation and is associated with poor survival in patients with IDH-wildtype glioblastoma. Inhibition of PIK3CA has been proposed as a potential therapeutic approach for IDH-wildtype glioblastoma.
- MYC: MYC is a transcription factor that is highly expressed in IDH-wildtype glioblastoma cancer cells. It is involved in the regulation of gene expression and is associated with poor survival in patients with IDH-wildtype glioblastoma. Inhibition of MYC has been proposed as a potential therapeutic approach for IDH-wildtype glioblastoma.
- MYCN: MYCN is a transcription factor that is highly expressed in IDH-wildtype glioblastoma cancer cells. It is involved in the regulation of gene expression and is associated with poor survival in patients with IDH-wildtype glioblastoma. Inhibition of MYCN has been proposed as a potential therapeutic approach for IDH-wildtype glioblastoma.
- FOXG1: FOXG1 is a transcription factor that is highly expressed in IDH-wildtype glioblastoma cancer cells. It is involved in the regulation of gene expression and is associated with poor survival in patients with IDH-wildtype glioblastoma. Inhibition of FOXG1 has been proposed as a potential therapeutic approach for IDH-wildtype glioblastoma.
- LAMC1: LAMC1 is a laminin subunit that is highly expressed in IDH-wildtype glioblastoma cancer cells. It is involved in the regulation of cell adhesion and is associated with poor survival in patients with IDH-wildtype glioblastoma. Inhibition of LAMC1 has been proposed as a potential therapeutic approach for IDH-wildtype glioblastoma.
- AKT1: AKT1 is a kinase that is highly expressed in IDH-wildtype glioblastoma cancer cells. It is involved in the regulation of cell survival and proliferation and is associated with poor survival in patients with IDH-wildtype glioblastoma. Inhibition of AKT1 has been proposed as a potential therapeutic approach for IDH-wildtype glioblastoma.
- TNF: TNF is a cytokine that is highly expressed in IDH-wildtype glioblastoma cancer cells. It is involved in the regulation of cell survival and proliferation and is associated with poor survival in patients with IDH-wildtype glioblastoma. Inhibition of TNF has been proposed as a potential therapeutic approach for IDH-wildtype glioblastoma.
- MEK/ERK: MEK/ERK is a signaling pathway that is highly expressed in IDH-wildtype glioblastoma cancer cells. It is involved in the regulation of cell survival and proliferation and is associated with poor survival in patients with IDH-wildtype glioblastoma. Inhibition of MEK/ERK has been proposed as a potential therapeutic approach for IDH-wildtype glioblastoma.
- ATM kinase: ATM kinase is a kinase that is highly expressed in IDH-wildtype glioblastoma cancer cells. It is involved in the regulation of cell survival and proliferation and is associated with poor survival in patients with IDH-wildtype glioblastoma. Inhibition of ATM kinase has been proposed as a potential therapeutic approach for IDH-wildtype glioblastoma.
- p-38α: p-38α is a kinase that is highly expressed in IDH-wildtype glioblastoma cancer cells. It is involved in the regulation of cell survival and proliferation and is associated with poor survival in patients with IDH-wildtype glioblastoma. Inhibition of p-38α has been proposed as a potential therapeutic approach for IDH-wildtype glioblastoma.
- SOX2: SOX2 is a transcription factor that is highly expressed in IDH-wildtype glioblastoma cancer cells. It is involved in the regulation of gene expression and is associated with poor survival in patients with IDH-wildtype glioblastoma. Inhibition of SOX2 has been proposed as a potential therapeutic approach for IDH-wildtype glioblastoma.
- STAT3: STAT3 is a transcription factor that is highly expressed in IDH-wildtype glioblastoma cancer cells. It is involved in the regulation of gene expression and is associated with poor survival in patients with IDH-wildtype glioblastoma. Inhibition of STAT3 has been proposed as a potential therapeutic approach for IDH-wildtype glioblastoma.
- PIK3CA: PIK3CA is a kinase that is highly expressed in IDH-wildtype glioblastoma cancer cells. It is involved in the regulation of cell survival and proliferation and is associated with poor survival in patients with IDH-wildtype glioblastoma. Inhibition of PIK3CA has been proposed as a potential therapeutic approach for IDH-wildtype glioblastoma.
- MYC: MYC is a transcription factor that is highly expressed in IDH-wildtype glioblastoma cancer cells. It is involved in the regulation of gene expression and is associated with poor survival in patients with IDH-wildtype glioblastoma. Inhibition of MYC has been proposed as a potential therapeutic approach for IDH-wildtype glioblastoma.
- MYCN: MYCN is a transcription factor that is highly expressed in IDH-wildtype glioblastoma cancer cells. It is involved in the regulation of gene expression and is associated with poor survival in patients with IDH-wildtype glioblastoma. Inhibition of MYCN has been proposed as a potential therapeutic approach for IDH-wildtype glioblastoma.
- FOXM1: FOXM1 is a transcription factor that is highly expressed in IDH-wildtype glioblastoma cancer cells. It is involved in the regulation of gene expression and is associated with poor survival in patients with IDH-wildtype glioblastoma. Inhibition of FOXM1 has been proposed as a potential therapeutic approach for IDH-wildtype glioblastoma.
- LAMB1: LAMB1 is a laminin subunit that is highly expressed in IDH-wildtype glioblastoma cancer cells. It is involved in the regulation of cell adhesion and is associated with poor survival in patients with IDH-wildtype glioblastoma. Inhibition of LAMB1 has been proposed as a potential therapeutic approach for IDH-wildtype glioblastoma.
- TNF: TNF is a cytokine that is highly expressed in IDH-wildtype glioblastoma cancer cells. It is involved in the regulation of cell survival and proliferation and is associated with poor survival in patients with IDH-wildtype glioblastoma. Inhibition of TNF has been proposed as a potential therapeutic approach for IDH-wildtype glioblastoma.
- TIE2: TIE2 is a receptor tyrosine kinase that is highly expressed in IDH-wildtype glioblastoma cancer cells. It is involved in the regulation of cell survival and proliferation and is associated with poor survival in patients with IDH-wildtype glioblastoma. Inhibition of TIE2 has been proposed as a potential therapeutic approach for IDH-wildtype glioblastoma.
- NTRK1: NTRK1 is a receptor tyrosine kinase that is highly expressed in IDH-wildtype glioblastoma cancer cells. It is involved in the regulation of cell survival and proliferation and is associated with poor survival in patients with IDH-wildtype glioblastoma. Inhibition of NTRK1 has been proposed as a potential therapeutic approach for IDH-wildtype glioblastoma.
- TEMs: TEMs are cells that are highly expressed in IDH-wildtype glioblastoma cancer cells. They are involved in the regulation of cell survival and proliferation and are associated with poor survival in patients with IDH-wildtype glioblastoma. Inhibition of TEMs has been proposed as a potential therapeutic approach for IDH-wildtype glioblastoma.
- p21: p21 is a protein that is highly expressed in IDH-wildtype glioblastoma cancer cells. It is involved in the regulation of cell survival and proliferation and is associated with poor survival in patients with IDH-wildtype glioblastoma. Inhibition of p21 has been proposed as a potential therapeutic approach for IDH-wildtype glioblastoma.
- TIE2-expressing monocytes: TIE2-expressing monocytes are cells that are highly expressed in IDH-wildtype glioblastoma cancer cells. They are involved in the regulation of cell survival and proliferation and are associated with poor survival in patients with IDH-wildtype glioblastoma. Inhibition of TIE2-expressing monocytes has been proposed as a potential therapeutic approach for IDH-wildtype glioblastoma.
- TIE2-expressing macrophages: TIE2-expressing macrophages are cells that are highly expressed in IDH-wildtype glioblastoma cancer cells. They are involved in the regulation of cell survival and proliferation and are associated with poor survival in patients with IDH-wildtype glioblastoma. Inhibition of TIE2-expressing macrophages has been proposed as a potential therapeutic approach for IDH-wildtype glioblastoma.
- HGF: HGF is a ligand for c-Met that is highly expressed in IDH-wildtype glioblastoma cancer cells. It is involved in various tumorigenic and stem cell-enriching pathways, including epithelial-to-mesenchymal transition, angiogenesis, proliferation, and invasion/metastasis. HGF has been implicated in therapeutic resistance and recurrence, and its expression is associated with poor survival in patients with IDH-wildtype glioblastoma.
- SHH: SHH is a signaling pathway that is highly expressed in IDH-wildtype glioblastoma cancer cells. It is involved in various tumorigenic and stem cell-enriching pathways, including epithelial-to-mesenchymal transition, angiogenesis, proliferation, and invasion/metastasis. SHH has been implicated in therapeutic resistance and recurrence, and its expression is associated with poor survival in patients with IDH-wildtype glioblastoma.
- STAT3: STAT3 is a transcription factor that is highly expressed in IDH-wildtype glioblastoma cancer cells. It is involved in the regulation of gene expression and is associated with poor survival in patients with IDH-wildtype glioblastoma. Inhibition of STAT3 has been proposed as
